Getinge’s Q3 Report: A Strong Quarter Amidst Global Market Momentum
As we navigate the ever-changing landscape of the medical technology industry, Getinge’s Q3 report sheds light on the company’s impressive performance. CEO Mattias Perjos and CFO Agneta Palmer Take the Stage
In a conference call on October 18, 2024, Mattias Perjos and Agneta Palmer presented the company’s key takeaways from the quarter. The atmosphere was electric as they delved into the details of Getinge’s remarkable growth.
A Quarter of Strong Global Market Momentum
The numbers speak for themselves: order intake growth surged by 10 percentage points, with a commendable 7.4% organic growth rate. This success can be attributed to positive developments across all business areas, except for life science, and a geographically diverse spread of order intake.
Net Sales and Gross Margin: A Mixed Bag
While net sales increased by 3.5% in the quarter, organic growth remained flat compared to last year. On the other hand, adjusted gross margin saw improvements in Life Science and Surgical Workflows, but decreased in Acute Care Therapies and for the group as a whole. This was largely due to unfavorable mix, inflation, and under-absorption.
Silver Linings: Healthy Price Increases and Solid Financial Position
Despite these challenges, healthy price increases signal that Getinge’s products remain attractive to customers. Moreover, the company’s financial position remains solid, even with increased financial leverage following the acquisition of Paragonix.
A Bright Future Ahead
As Getinge continues to ride the wave of global market momentum, it’s clear that the company is poised for success. With a solid financial foundation and a strong product portfolio, the future looks bright for this medical technology leader.
Leave a Reply